Status:
COMPLETED
Ferumoxytol Enhanced Hyperfine Low Field Strength MRI
Lead Sponsor:
University of Pennsylvania
Conditions:
Anemia, Hemolytic
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this pilot study is to evaluate the feasibility of using Ferumoxytol as a contrast agent on a low field strength, portable magnetic resonance imaging (MRI) system. Participants receivin...
Detailed Description
Ferumoxytol is a superparamagnetic iron oxide nanoparticle (SPION) preparation that was originally designed as an MRI contrast agent, but later received FDA approval as a treatment for iron deficiency...
Eligibility Criteria
Inclusion
- Age 18 years or older
- Prescribed Ferumoxytol for iron deficiency anemia
- Informed consent obtained from patient or a legally authorized representative
Exclusion
- Contraindications to routine 1.5 T MRI evaluation, including:
- Electrical implants such as cardiac pacemakers or perfusion pumps
- Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts or heart valves with steel parts, metal fragments, shrapnel, tattoos near the eye, steel implants, or other irremovable ferromagnetic objects
- History of uncontrolled seizures
- Claustrophobia
- Weight greater than or equal to 400 lbs (181.4 kg)
- Pregnancy
- Inability or suspected inability to comply with the study procedures
Key Trial Info
Start Date :
November 9 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 29 2022
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04721262
Start Date
November 9 2020
End Date
August 29 2022
Last Update
December 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104